TYPE Correction PUBLISHED 21 November 2022 DOI 10.3389/fimmu.2022.1078003 Corrigendum: Ligand- OPEN ACCESS based CAR T-cell: Different EDITED AND REVIEWED BY Catherine Sautes-Fridman, INSERM U1138 Centre de Recherche strategies to drive T-cells des Cordeliers (CRC), France *CORRESPONDENCE in future new treatments Manel Juan mjuan@clinic.cat Alejandro Ramı́rez-Chacón 1,2, Sergi Betriu-Méndez 3,4, SPECIALTY SECTION This article was submitted to Ariadna Bartoló-Ibars 3,4, Azucena González 3,4,5, Mercè Martı́ 1,2 Cancer Immunity and Immunotherapy, and Manel Juan 3,4,5* a section of the journal 1 Immunology Unit, Department of Cellular Biology, Physiology and Immunology, Universitat Autònoma Frontiers in Immunology de Barcelona (UAB), Cerdanyola del Vallès, Spain, 2Laboratory of Cellular Immunology, Institute of RECEIVED 23 October 2022 Biotechnology and Biomedicine (IBB), Cerdanyola del Vallès, Spain, 3Immunology Department, Hospital ACCEPTED 09 November 2022 Cl´ınic de Barcelona, Centre de Diagnòstic Biomèdic (CDB), Barcelona, Spain, 4Immunology PUBLISHED 21 November 2022 Department, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) –Fundació Clı´nic per a la Recerca Biomèdica (FCRB) Universitat de Barcelona (UB), Barcelona, Spain, 5Immunology Department, CITATION Hospital Sant Joan de Déu, Barcelona, Spain Ramı´rez-Chacón A, Betriu-Méndez S, Bartoló-Ibars A, González A, Martı´ M and Juan M (2022) Corrigendum: KEYWORDS Ligand-based CAR T-cell: Different strategies to drive T-cells in future T cells, chimeric antigen receptor (CAR), ligands, receptor, antigen, CAAR, BAR new treatments. Front. Immunol. 13:1078003. doi: 10.3389/fimmu.2022.1078003 COPYRIGHT © 2022 Ramı´rez-Chacón, A corrigendum on Betriu-Méndez, Bartoló-Ibars, González, Ligand-based CAR-T cell: Different strategies to drive T cells in future Martı´ and Juan. This is an open-access article distributed under the terms of new treatments the Creative Commons Attribution by Ramıŕ ez-Chacó n A, Betriu-Mé ndez S, Bartoló -Ibars A, Gonzá lez A, Martı ́ M and Juan M License (CC BY). The use, distribution (2022) Front. Immunol. 13:932559. doi: 10.3389/fimmu.2022.932559 or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic In the published article, there was an error in the Funding statement. Missing grant practice. No use, distribution or supporting this manuscript. The correct Funding statement appears below. reproduction is permitted which does not comply with these terms. Funding “Thanks to Immunology department (Hospital Clı́nic de Barcelona) and Institute of Biotechnology and Biomedicine (IBB-UAB) for their help during the writing of this article. This work has been partially supported by grants from the Instituto de Salud Carlos III, Spanish Ministry of Health (FIS PI18/00775, PICI18/00012 and complementary grant for CONCORD-023), Fondo Europeo de Desarrollo Regional (FEDER) “una manera de hacer Europa”, “La Caixa” Foundation (CP042702/LCF/PR/ GN18/50310007), and Secretaria d’Universitats i Recerca del Departament d’Empresa i Coneixement, Generalitat de Catalunya, project 2020PANDE00079.” The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated. Frontiers in Immunology 01 frontiersin.org Ramı́rez-Chacón et al. 10.3389/fimmu.2022.1078003 Publisher’s note organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or All claims expressed in this article are solely those of the claim that may be made by its manufacturer, is not guaranteed authors and do not necessarily represent those of their affiliated or endorsed by the publisher. Frontiers in Immunology 02 frontiersin.org